FDA Approves Upadacitinib for Adults With Moderately to Severely Active Crohn Disease
May 18th 2023In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.
Read More
Pegfilgrastim Biosimilar for Treatment of Neutropenia Launches
May 17th 2023Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.
Read More
Adolescents, Young Adults With Advanced Heart Disease Want More Active Role in Decision-Making
May 15th 2023Approximately 56.6% of young adults with advanced heart disease prefer to be involved in end-of-life decisions if they were very ill, with nearly all patients saying that they would also like their parents to be involved.
Read More